About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Oracle Healthcare Acquisition and Precision Therapeutics Announce Merger | Main | Why Does Flu Season Happen in Winter? »

December 04, 2007

Biovail and Watson Settle Cardizem® Suit

    By Sherri Oslick --

Biovail Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, and Watson Pharmaceuticals, Inc., have announced that they have reached a settlement agreement in Biovail's lawsuit against Andrx Pharmaceuticals, Inc., a subsidiary of Watson.  The lawsuit was filed following a paragraph IV certification as part of Andrx's filing of an ANDA to manufacture a generic version of Biovail's Cardizem® LA (diltiazem), which is used to treat hypertension and for the management of chronic stable angina.

Logo_watson Under the terms of the settlement, Watson, which has been awarded an exclusive license to the patents covering Cardizem® LA, will not enter the market until April 1, 2009.  At that time, Biovail will receive a royalty based on Watson's sales of its generic diltiazem.  Other details of the settlement agreement, which is subject to court approval, have not been disclosed.

For additional information regarding the settlement, please see:

Posted at 11:28 PM in Patent Litigation |

Comments

The comments to this entry are closed.

April 2025

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

Categories

Archives

More...